BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30924488)

  • 1. 2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach.
    Schehr M; Ianes C; Weisner J; Heintze L; Müller MP; Pichlo C; Charl J; Brunstein E; Ewert J; Lehr M; Baumann U; Rauh D; Knippschild U; Peifer C; Herges R
    Photochem Photobiol Sci; 2019 Jun; 18(6):1398-1407. PubMed ID: 30924488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
    Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
    J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of 4-fluorophenyl-imidazole p38α MAPK, CK1δ and JAK2 kinase inhibitors.
    Seerden JP; Leusink-Ionescu G; Woudenberg-Vrenken T; Dros B; Molema G; Kamps JA; Kellogg RM
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3412-8. PubMed ID: 24930833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.
    Halekotte J; Witt L; Ianes C; Krüger M; Bührmann M; Rauh D; Pichlo C; Brunstein E; Luxenburger A; Baumann U; Knippschild U; Bischof J; Peifer C
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28338621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors.
    Schulte AM; Kolarski D; Sundaram V; Srivastava A; Tama F; Feringa BL; Szymanski W
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
    Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors.
    El-Gokha A; Laufer SA; Koch P
    Org Biomol Chem; 2015 Nov; 13(43):10699-704. PubMed ID: 26351018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
    Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
    Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
    Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
    ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
    Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
    Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold.
    Scior T; Domeyer DM; Cuanalo-Contreras K; Laufer SA
    Curr Med Chem; 2011; 18(10):1526-39. PubMed ID: 21428890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1δ/ε inhibitors: Synthesis, biological evaluation and molecular modeling studies.
    Karthikeyan C; Jharia P; Waiker DK; Nusbaum AC; Amawi H; Kirwen EM; Christman R; Arudra SKC; Meijer L; Tiwari AK; Trivedi P
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2663-2667. PubMed ID: 28487075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib.
    Heintze L; Schmidt D; Rodat T; Witt L; Ewert J; Kriegs M; Herges R; Peifer C
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase and GPCR polypharmacological approach for the identification of efficient anticancer medicines.
    Park H; Jung HY; Mah S; Kim K; Hong S
    Org Biomol Chem; 2020 Oct; 18(41):8402-8413. PubMed ID: 33112339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor.
    Long A; Zhao H; Huang X
    J Med Chem; 2012 Jan; 55(2):956-60. PubMed ID: 22168824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.